Biohaven Ltd. (BHVN)
NYSE: BHVN ยท Real-Time Price ยท USD
12.85
-0.80 (-5.86%)
Nov 20, 2026, 12:01 PM EST - Market open
Biohaven Earnings Call Transcripts
Fiscal Year 2024
-
Troriluzole demonstrated a 50%-70% reduction in SCA progression over three years, with significant delays in disease decline and reduced fall risk, meeting all primary and secondary endpoints. The therapy was safe, well-tolerated, and is poised for FDA and EMA submissions, potentially becoming the first approved treatment for SCA.